Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group.

N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.

2.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
3.

Vemurafenib: in unresectable or metastatic melanoma.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000. Review.

PMID:
22946753
4.

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.

Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R.

Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5. Review.

5.

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.

Heakal Y, Kester M, Savage S.

Ann Pharmacother. 2011 Nov;45(11):1399-405. doi: 10.1345/aph.1Q363. Epub 2011 Oct 25. Review.

PMID:
22028422
6.

Vemurafenib.

Garbe C, Abusaif S, Eigentler TK.

Recent Results Cancer Res. 2014;201:215-25. doi: 10.1007/978-3-642-54490-3_13. Review.

PMID:
24756795
7.

Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.

Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, Marshall E, Plummer R, Proudlove C.

Pharmacoeconomics. 2013 Dec;31(12):1121-9. doi: 10.1007/s40273-013-0094-x. Review.

PMID:
24114739
8.

Dabrafenib therapy for advanced melanoma.

Trinh VA, Davis JE, Anderson JE, Kim KB.

Ann Pharmacother. 2014 Apr;48(4):519-29. doi: 10.1177/1060028013513009. Epub 2013 Nov 20. Review.

PMID:
24259661
9.

Drug safety evaluation of vemurafenib in the treatment of melanoma.

Tsai KY, Nowroozi S, Kim KB.

Expert Opin Drug Saf. 2013 Sep;12(5):767-75. doi: 10.1517/14740338.2013.813017. Epub 2013 Jun 26. Review.

PMID:
23800008
10.

Vemurafenib for the treatment of melanoma.

Jordan EJ, Kelly CM.

Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. Review.

PMID:
23094782
11.

[Vemurafenib (Zelboraf) in the therapy of melanoma].

Liszkay G.

Magy Onkol. 2013 Jun;57(2):110-3. doi: MagyOnkol.2013.57.2.110. Epub 2013 May 14. Review. Hungarian.

12.

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.

Sharma A, Shah SR, Illum H, Dowell J.

Drugs. 2012 Dec 3;72(17):2207-22. doi: 10.2165/11640870-000000000-00000. Review.

PMID:
23116250
13.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
14.

The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.

Brown MP, Long GV.

Asia Pac J Clin Oncol. 2014 Apr;10 Suppl S3:1-15. doi: 10.1111/ajco.12200. Review.

PMID:
24712861
15.

Dabrafenib and its potential for the treatment of metastatic melanoma.

Menzies AM, Long GV, Murali R.

Drug Des Devel Ther. 2012;6:391-405. doi: 10.2147/DDDT.S38998. Epub 2012 Dec 11. Review.

16.

Vemurafenib and ipilimumab: new agents for metastatic melanoma.

Banaszynski M, Kolesar JM.

Am J Health Syst Pharm. 2013 Jul 15;70(14):1205-10. doi: 10.2146/ajhp120260. Review.

PMID:
23820456
17.

Vemurafenib in melanoma.

Shaw HM, Nathan PD.

Expert Rev Anticancer Ther. 2013 May;13(5):513-22. doi: 10.1586/era.13.24. Review.

PMID:
23617343
18.

[Adverse skin reactions induced by BRAF inhibitors: a systematic review].

Sibaud V, Lamant L, Maisongrosse V, Delord JP.

Ann Dermatol Venereol. 2013 Aug-Sep;140(8-9):510-20. doi: 10.1016/j.annder.2013.02.031. Epub 2013 Jun 19. Review. French.

PMID:
24034635
19.

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.

Swaika A, Crozier JA, Joseph RW.

Drug Des Devel Ther. 2014 Jun 16;8:775-87. doi: 10.2147/DDDT.S31143. eCollection 2014. Review.

20.

Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.

Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, Coto-Segura P, Vazquez-Lopez F, Perez-Oliva N.

Dermatol Online J. 2013 Apr 15;19(4):16. Review.

Items per page

Supplemental Content

Write to the Help Desk